How many drugs treat Malignant neoplasm of breast?

Drug Landscape tracks 4 marketed treatments for Malignant neoplasm of breast (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/malignant-neoplasm-of-breast.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Malignant neoplasm of breast — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Malignant neoplasm of breast (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Malignant neoplasm of breast, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Bevacizumab	Bevacizumab-Bvzr	Roche	Monoclonal antibody	Vascular Endothelial Growth Factor (VEGF)	2004-01-01
Avastin	bevacizumab	Roche	Vascular Endothelial Growth Factor Inhibitor [EPC]	Vascular endothelial growth factor A	2004-01-01
Avastin	Avastin	Washington University School of Medicine		Vascular endothelial growth factor A
Metholone	drostanolone propionate	Eli Lilly	drostanolone propionate	Androgen receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Roche · 2 drugs in Malignant neoplasm of breast
Eli Lilly · 1 drug in Malignant neoplasm of breast
Washington University School of Medicine · 1 drug in Malignant neoplasm of breast

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Malignant neoplasm of breast:

Cite this brief

Drug Landscape (2026). Malignant neoplasm of breast — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/malignant-neoplasm-of-breast. Accessed 2026-06-10.

Malignant neoplasm of breast full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing